BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Thryv Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Thryv Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07277582-650@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:THRV-1268: Phase 2/3 readout est. (NCT07277582)
DESCRIPTION:THRV-1268\, phase 2/3.\nStudy: Evaluation of the Efficacy and S
 afety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) an
 d Type 3 (LQTS3)\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/thrv-1268#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07277582
URL:https://assetmemo.bio/drug/thrv-1268#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
